# Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer

> **NCT06745219** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 30 (estimated)

## Conditions studied

- Thrombopenia
- Cervical Cancer
- Radiotherapy Side Effect
- Chemotherapeutic Toxicity

## Interventions

- **DRUG:** herombopag

## Key facts

- **NCT ID:** NCT06745219
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-07-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06745219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06745219, "Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06745219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*